Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Jun;20(6):395-402.
doi: 10.1089/dia.2018.0150. Epub 2018 Jun 14.

Accuracy of a Factory-Calibrated, Real-Time Continuous Glucose Monitoring System During 10 Days of Use in Youth and Adults with Diabetes

Affiliations

Accuracy of a Factory-Calibrated, Real-Time Continuous Glucose Monitoring System During 10 Days of Use in Youth and Adults with Diabetes

R Paul Wadwa et al. Diabetes Technol Ther. 2018 Jun.

Abstract

Background: Frequent use of continuous glucose monitoring (CGM) systems is associated with improved glycemic outcomes in persons with diabetes, but the need for calibrations and sensor insertions are often barriers to adoption. In this study, we evaluated the performance of G6, a sixth-generation, factory-calibrated CGM system specified for 10-day wear.

Methods: The study enrolled participants of ages 6 years and up with type 1 diabetes or insulin-treated type 2 diabetes at 11 sites in the United States. Participation involved one sensor wear period of up to 10 days. Adults wore the system on the abdomen; youth of ages 6-17 years could choose to wear it on the abdomen or upper buttocks. Clinic sessions for frequent comparison with reference blood glucose measurements took place on days 1, 4-5, 7, and/or 10. Participants of ages 13 years and up underwent purposeful supervised glucose manipulation during in-clinic sessions. During the study, participants calibrated the systems once daily. However, analysis was performed on glucose values that were derived from reprocessed raw sensor data, independently of self-monitored blood glucose values used for calibration. Reprocessing used assigned sensor codes and a factory-calibration algorithm. Performance evaluation included the proportion of CGM values that were within ±20% of reference glucose values >100 mg/dL or within ±20 mg/dL of reference glucose values ≤100 mg/dL (%20/20), the analogous %15/15, and the mean absolute relative difference (MARD, expressed as a percentage) between temporally matched CGM and reference values.

Results: Data from 262 study participants (21,569 matched CGM reference pairs) were analyzed. The overall %15/15, %20/20, and MARD were 82.4%, 92.3%, and 10.0%, respectively. Matched pairs from 134 adults and 128 youth of ages 6-17 years were similar with respect to %20/20 (92.4% and 91.9%) and MARD (9.9% and 10.1%). Overall %20/20 values on days 1 and 10 of sensor wear were 88.6% and 90.6%, respectively. The system's "Urgent Low Soon" (predictive of hypoglycemia within 20 min) hypoglycemia alert was correctly provided 84% of the time within 30 min before impending biochemical hypoglycemia (<70 mg/dL). The 10-day sensor survival rate was 87%.

Conclusion: The new factory-calibrated G6 real-time CGM system provides accurate readings for 10 days and removes several clinical barriers to broader CGM adoption.

Keywords: Advanced algorithm; Clinical accuracy; Continuous glucose monitoring; Factory-calibrated; Glucose sensor performance; MARD.

PubMed Disclaimer

Conflict of interest statement

R.P.W reports research support from Dexcom, Bigfoot Biomedical, MannKind Corporation, Novo Nordisk, Helmsley Charitable Trusty and NIH/NIDDK and advisory board consulting fees from Eli Lilly and Company.

L.M.L. has served as a consultant or on advisory boards for Lilly, NovoNordisk, Sanofi, Roche, Johnson & Johnson, Boehringer Ingelheim, AstraZeneca, Mannkind, Dexcom, Insulet, Senseonics, Unomedical, and Menarini.

V.N.S.' employer has received research support from the Sanofi US, Dexcom Inc, Eyenuk, and Jaeb Center for Health Research. V.N.S. served on advisory board of Sanofi US and received speaking fees from Dexcom Inc.

S.K.G. has received Advisory Board Consulting fees from Medtronic, Roche, Merck, Lexicon, Novo Nordisk, Sanofi, Mannkind, Senseonics, Zealand, and Eli Lilly. S.K.G. has received research grants through the University of Colorado Denver from Eli Lilly, Novo-Nordisk, Merck, Lexicon, Medtronic, Dario, NCI, T1D Exchange, NIDDK, JDRF, Animas, Dexcom, and Sanofi. S.K.G. does not own stocks in any device or pharmaceutical company.

Figures

<b>FIG. 1.</b>
FIG. 1.
Kaplan–Meier curve of sensor life (n = 285). The shaded area represents the 95% confidence interval.
<b>FIG. 2.</b>
FIG. 2.
Comparison of CGM and YSI values with different CGM calibration regimens. Triangles, YSI values; blue lines, CGM values from factory-calibration regimen; orange lines, CGM values from once-daily calibration regimen. (A) Better CGM–YSI agreement with the once-daily calibration regimen. (B) Better CGM–YSI agreement with the factory-calibration regimen. (C) Equivalent performance of the two calibration regimens. CGM, continuous glucose monitoring; YSI, yellow springs instrument.

Similar articles

Cited by

References

    1. Miller K, Foster N, DeSalvo D, et al. : Continuous glucose monitoring (CGM) use in type 1 diabetes: An update from the T1D exchange clinic registry. Pediatric Diabetes 2016;17(S24):49. - PubMed
    1. Hoss U, Budiman ES: Factory-calibrated continuous glucose sensors: the science behind the technology. Diabetes Technol Ther 2017;19(S2):S44–S50 - PMC - PubMed
    1. Olafsdottir AF, Attvall S, Sandgren U, et al. : A clinical trial of the accuracy and treatment experience of the flash glucose monitor freestyle Libre in adults with type 1 diabetes. Diabetes Technol Ther 2017;19:164–172 - PMC - PubMed
    1. FDA authorizes first fully interoperable continuous glucose monitoring system, streamlines review pathway for similar devices. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm602870.htm Accessed May14, 2018
    1. Clukey R, North B, Parkin C: Utilization of human factors analysis throughout product development enhances usability of CGM sensor applicators. Diabetes 2017;67(S1):A184

Publication types

MeSH terms